Heng Chi1, Bettina E Hansen1, Simin Guo2, Ning Ping Zhang3, Xun Qi4, Liang Chen4, Qing Guo2, Pauline Arends1, Ji-Yao Wang3, Elke Verhey1, Robert J de Knegt1, Qing Xie2, Harry L A Janssen1,5. 1. Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands. 2. Department of Infectious Diseases, Ruijin Hospital, Jiaotong University, Shanghai, China. 3. Department of Gastroenterology and Hepatology, Zhongshan Hospital, Shanghai, China. 4. Department of Hepatitis Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. 5. Toronto Centre for Liver Disease, University Health Network, Toronto General Hospital, University of Toronto, Canada.
Abstract
Background: We studied whether 48 weeks of pegylated interferon alfa-2b (peginterferon) add-on therapy increases serological response in hepatitis B virus (HBV) envelope antigen (HBeAg)-positive patients receiving nucleos(t)ide analogue (NA) therapy, compared with continued NA monotherapy. Methods: This randomized trial included HBeAg-positive patients with compensated liver disease who were treated withentecavir/tenofovirfor >12 months and had an HBV DNA load of <2000 IU/mL. Patients were randomly assigned in a 1:1 ratio to 48 weeks of peginterferon add-on therapy (n = 39) or continued NA monotherapy (n = 38). Response (defined as HBeAg seroconversion with an HBV DNA load of <200 IU/mL) was assessed at week 48, with responders discontinuing NA therapy at week 72. Results: The primary end point (response at week 96) was achieved in 18% of patients who were assigned peginterferon add-on therapy versus 8% of patients assigned NA monotherapy (P = .31). Among 58 interferon-naive patients, add-on therapy led to a greater frequency of HBeAg seroconversion (30% vs 7%; P = .034) and response (26% vs 7%; P = .068) at week 96, compared with monotherapy. Among 8 responders at week 48 who discontinued NA therapy at week 72, 6 patients (75%) maintained a response until week 96 (4 of 6 [67%] in the add-on therapy group vs 2 of 2 [100%] in the monotherapy group; P = 1.00). Adverse events were mainly related to peginterferon. Conclusion: The primary end point was negative, but peginterferon add-on therapy appeared to result in a greater frequency of HBeAg seroconversion, compared with NA monotherapy, in interferon-naive patients receiving NA therapy. Clinical Trials Registration: NCT01532843.
RCT Entities:
Background: We studied whether 48 weeks of pegylated interferon alfa-2b (peginterferon) add-on therapy increases serological response in hepatitis B virus (HBV) envelope antigen (HBeAg)-positive patients receiving nucleos(t)ide analogue (NA) therapy, compared with continued NA monotherapy. Methods: This randomized trial included HBeAg-positive patients with compensated liver disease who were treated with entecavir/tenofovir for >12 months and had an HBV DNA load of <2000 IU/mL. Patients were randomly assigned in a 1:1 ratio to 48 weeks of peginterferon add-on therapy (n = 39) or continued NA monotherapy (n = 38). Response (defined as HBeAg seroconversion with an HBV DNA load of <200 IU/mL) was assessed at week 48, with responders discontinuing NA therapy at week 72. Results: The primary end point (response at week 96) was achieved in 18% of patients who were assigned peginterferon add-on therapy versus 8% of patients assigned NA monotherapy (P = .31). Among 58 interferon-naive patients, add-on therapy led to a greater frequency of HBeAg seroconversion (30% vs 7%; P = .034) and response (26% vs 7%; P = .068) at week 96, compared with monotherapy. Among 8 responders at week 48 who discontinued NA therapy at week 72, 6 patients (75%) maintained a response until week 96 (4 of 6 [67%] in the add-on therapy group vs 2 of 2 [100%] in the monotherapy group; P = 1.00). Adverse events were mainly related to peginterferon. Conclusion: The primary end point was negative, but peginterferon add-on therapy appeared to result in a greater frequency of HBeAg seroconversion, compared with NA monotherapy, in interferon-naive patients receiving NA therapy. Clinical Trials Registration: NCT01532843.
Authors: Willem P Brouwer; Henry L Y Chan; Pietro Lampertico; Jinlin Hou; Pisit Tangkijvanich; Hendrik W Reesink; Wenhong Zhang; Alessandra Mangia; Tawesak Tanwandee; Giuseppe Montalto; Kris Simon; Necati Ormeci; Liang Chen; Fehmi Tabak; Fulya Gunsar; Robert Flisiak; Peter Ferenci; Meral Akdogan; Filiz Akyuz; Nattiya Hirankarn; Louis Jansen; Vincent Wai-Sun Wong; Roberta Soffredini; Xieer Liang; Shalom Chen; Zwier M A Groothuismink; Rosanna Santoro; Jerzy Jaroszewicz; Resat Ozaras; Karin Kozbial; Mayur Brahmania; Qing Xie; Watcharasak Chotiyaputta; Qi Xun; Monika Pazgan-Simon; Erkin Oztas; Elke Verhey; Noé R Montanari; Jian Sun; Bettina E Hansen; Andre Boonstra; Harry L A Janssen Journal: Clin Infect Dis Date: 2019-11-13 Impact factor: 9.079
Authors: Kin Seng Liem; Margo J H van Campenhout; Qing Xie; Willem Pieter Brouwer; Heng Chi; Xun Qi; Liang Chen; Fehmi Tabak; Bettina E Hansen; Harry L A Janssen Journal: Aliment Pharmacol Ther Date: 2019-02 Impact factor: 8.171
Authors: Laura Ambra Nicolini; Andrea Orsi; Paola Tatarelli; Claudio Viscoli; Giancarlo Icardi; Laura Sticchi Journal: Int J Environ Res Public Health Date: 2019-09-09 Impact factor: 3.390